Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Anebulo Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Anebulo Pharmaceuticals, Inc.

ANEB

Anebulo Pharmaceuticals, Inc.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing selonabant, a cannabinoid receptor type-1 (CB1) antagonist designed to treat cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication (ACI). The company’s lead product candidate, available in oral and intravenous formulations, aims to rapidly reverse cannabis-induced symptoms. Anebulo targets emergency departments and vulnerable populations, particularly pediatric patients, addressing a growing unmet medical need in the U.S. cannabis market.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Anebulo Pharmaceuticals, Inc.

1
1
Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals Reports Decrease in Net Loss and Strategic Shift in Development

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals Reports $2.16 Million Net Loss, Focuses on Selonabant Development

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals Reports $8.5 Million Net Loss for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals Reports $1.68 Million Net Loss and Strategic Shift to IV Selonabant Development

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals Reports Decreased Net Loss and Improved Cash Position in Latest 10-Q

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals Reports Improved Net Loss, Reduced Operating Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments